# US 10,869,834 B2 · Treatment of inflammatory bowel disease > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,869,834 B2 - Document ID: US10869834B2 - Status: Granted - Kind: B2 - Application number: 16/091,312 - Filed: 2017-04-06 - Published: 2019-05-23 - Granted: 2020-12-22 - Earliest claimed: 2016-04-07 - Assignees: University College Dublin, National University of Ireland, Dublin - Applicants: University College Dublin, National University of Ireland, Dublin - Inventors: Ulla Knaus - Web page: https://patentgrep.com/patent/US10869834B2 ## CPC - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 9/5005: {Wall or coating material} - A61K 33/40: Peroxides - A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00) - A61K 38/443: {acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)} - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61K 9/4858: {Organic compounds} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A delivery system comprising hydrogen peroxide or a hydrogen peroxide generator system, for use in a method for the treatment or prevention of inflammatory bowel disease in a mammal, is described. The method comprises a step of orally administering to the mammal the delivery system, wherein the delivery system is formulated for oral delivery and release of the hydrogen peroxide or hydrogen peroxide generator system in-situ at a target location in the mammalian gastrointestinal tract. Also described is an oral dosage delivery system comprising hydrogen peroxide or a hydrogen peroxide generator system, in which the delivery system is configured for oral administration to a mammal and release of the hydrogen peroxide or hydrogen peroxide generator system at a target location within the mammalian gastrointestinal tract thereby effecting a localised increase in hydrogen peroxide levels at the target location in the mammalian gut or airways. ## Claims ### Claim 1 A method for the treatment of inflammatory bowel disease in a mammal in need thereof, in which the method comprises a step of orally administering to the mammal a delivery system comprising hydrogen peroxide or a hydrogen peroxide generator system, wherein the delivery system is formulated for oral delivery and release of the hydrogen peroxide or hydrogen peroxide generator system in-situ at a target location in the mammalian gastrointestinal tract. ### Claim 2 (depends on 1) A method according to claim 1, in which the delivery system is formulated for release of the hydrogen peroxide or the hydrogen peroxide generator system in-situ in the colon. ### Claim 3 (depends on 1) A method according to claim 1, in which the hydrogen peroxide generator system comprises an enzyme and substrate configured to react in-situ at a target location in the mammalian gastrointestinal tract to produce hydrogen peroxide. ### Claim 4 (depends on 1) A method according to claim 1, in which the hydrogen peroxide generator system comprises an enzyme and substrate configured to react in-situ at a target location in the mammalian gastrointestinal tract to produce hydrogen peroxide, in which the substrate is glucose and the enzyme is glucose oxidase. ### Claim 5 (depends on 1) A method according to claim 1, in which the hydrogen peroxide generator system is substantially free of water. ### Claim 6 (depends on 3) A method according to claim 3, in which the hydrogen peroxide generator system is configured to keep the enzyme and substrate separate prior to release of the enzyme and substrate at the target location in the gastrointestinal tract. ### Claim 7 (depends on 3) A method according to claim 3 in which the enzyme is provided as a first particulate composition and the substrate is provided as a second particulate composition, optionally in which the first particulate composition and second particulate composition are each, independently, selected from microparticles, microspheres, nanoparticles, and granulated particles. ### Claim 8 (depends on 7) A method according to claim 7, in which the first and second particulate compositions are contained within a container configured to release the compositions at a target location within the gastrointestinal tract, in which the container is optionally an enteric coating. ### Claim 9 (depends on 1) A method according to claim 1, in which the delivery system comprises hydrogen peroxide. ### Claim 10 (depends on 1) A method according to claim 1, in which the delivery system comprises a polymeric matrix configured for slow release of hydrogen peroxide in-situ at the target location in the gastrointestinal tract. ### Claim 11 (depends on 1) A method according to claim 1, in which the hydrogen peroxide generator system comprises an active agent capable of localised stimulation of the mammalian epithelial tissue to produce hydrogen peroxide in-situ at the target location in the gastrointestinal tract, in which the active agent is optionally an agonist that enhances NOX1 or DUOX2 expression and/or activity. ### Claim 12 (depends on 1) A method according to claim 1, in which the hydrogen peroxide generator system is a bacterium that produces hydrogen peroxide. ### Claim 13 (depends on 1) A method according to claim 1, in which the hydrogen peroxide generator system is a bacterium that produces hydrogen peroxide, and in which the bacterium is genetically engineered to overexpress hydrogen peroxide. ### Claim 14 (depends on 1) A method according to claim 1, in which the delivery system is configured to release or generate 5 nmol to 20 μmol hydrogen peroxide in-situ at the target location in the gastrointestinal tract. ### Claim 15 (depends on 1) A method according to claim 1, in which the inflammatory bowel disease is ulcerative colitis or Crohn's disease, optionally in which the delivery system is administered during a remission phase of the disease to treat acute recurrence of the symptoms of the disease.